CoChat

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity

Open access
Trapp, Christine M., Censani, Marisa · 2023 · Current Opinion in Endocrinology, Diabetes & Obesity

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Purpose of review: Examine Setmelanotide use in patients with rare genetic variants that disrupt the melanocortin pathway. Recent findings: Between February 2017 and September 2018, 10 participants with pro-opiomelanocortin (POMC)/ proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency and 11 participants with leptin receptor (LEPR) deficiency were enrolled in open-label, phase 3 trials at 10 centers in the United States and internationally to assess the efficacy and safety of the melanocortin-4 receptor (MC4R) agonist Setmelanotide. 80% of POMC participants and 45% of LEPR participants achieved at least 10% weight loss at 1 year. Significant changes in hunger scores were seen for both cohorts as well. Setmelanotide was well tolerated with injection site reactions and hyperpigmentation being the most common adverse events reported. As a result, Setmelanotide was approved by the U.S. FDA in 2020 for chronic weight management in adult and pediatric patients ≥6 years of age with POMC, LEPR, or PCSK1 deficiency. In 2022, its approval was extended to include patients with Bardet–Biedel syndrome (BBS) after phase 3 trial data showed that, on average, Setmelanotide treatment resulted in a BMI loss of 7.9% for the 44 BBS participants. Summary: Rare genetic variants such as POMC, LEPR, and PCSK1 deficiency disrupt MC4R pathway signaling, resulting in severe early-onset obesity, hyperphagia, and increased risk for metabolic co-morbidities. Patients with BBS also demonstrate severe early-onset obesity and hyperphagia, due in part to defective MC4R signaling. Setmelanotide has shown promising benefits in improving satiety scores and weight-related outcomes in patients with these early-life genetic obesity conditions, although longer-term studies are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/med.0000000000000798

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Box 1 no caption available
Box 1 no caption availableCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 41

Metadata

Authors
Trapp, C. M., & Censani, M.
Affiliations
  • University of Connecticut (US)
  • NewYork–Presbyterian Hospital (US)
Corresponding author
Censani, Marisa
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Published
2023-02-01
Volume
30
Issue
2
Pages
136-140
ISSN
  • 1752-296X (ISSN-L)
  • 1752-2978
OpenAlex
W4318754718
Cited by
41
References
23
Citations by year
2026: 5 · 2025: 9 · 2024: 19 · 2023: 8
FWCI
6.10
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
setmelanotide, melanocortin-4 receptor agonist, genetic obesity, leptin receptor deficiency, Bardet-Biedl syndrome, childhood obesity, weight loss, hyperphagia, satiety, melanocortin pathway, drug approval
MeSH terms
Adrenal Insufficiency, alpha-MSH, Child, Humans, Hyperphagia, Obesity, Pro-Opiomelanocortin, Clinical Trials, Phase III as Topic, Pediatric Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. https://app.cochat.ai/papers/10.1097/med.0000000000000798
The paper
Trapp, C. M., & Censani, M. (2023). Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000798

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.